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Introduction {#embj2018100409-sec-0001}
============

Hematopoietic stem cells (HSCs) are a specialized subset of cells equipped with two cardinal features, self‐renewal and multi‐lineage differentiation potency, which are critical for their function in bone marrow transplantation (Orkin & Zon, [2008](#embj2018100409-bib-0029){ref-type="ref"}). The regulation of HSC self‐renewal and differentiation in balance with proliferation and apoptosis governs the size and functional capacity of the stem cell pool, while defects in such regulation can result in leukemic transformation or depletion of normal hematopoietic activity (Yilmaz *et al*, [2006](#embj2018100409-bib-0045){ref-type="ref"}; Pietras *et al*, [2011](#embj2018100409-bib-0033){ref-type="ref"}; Wagers, [2012](#embj2018100409-bib-0042){ref-type="ref"}). Recent studies have revealed multiple important HSC regulators and suggest that an orchestrated interaction among cell‐intrinsic signals (transcription factors, cell surface receptors, cell cycle regulators, and signal transducers) and extrinsic mediators (bone marrow niche components and soluble growth factors) controls HSC fate (Orkin & Zon, [2008](#embj2018100409-bib-0029){ref-type="ref"}; Wilson *et al*, [2009](#embj2018100409-bib-0044){ref-type="ref"}; Ehninger & Trumpp, [2011](#embj2018100409-bib-0006){ref-type="ref"}; Gazit *et al*, [2013](#embj2018100409-bib-0008){ref-type="ref"}). Furthermore, growing evidence suggests a link between the metabolic activity of HSCs and their capacity to preserve stem cell functions and hematopoietic differentiation potential (Yu *et al*, [2013](#embj2018100409-bib-0046){ref-type="ref"}; Burgess *et al*, [2014](#embj2018100409-bib-0004){ref-type="ref"}; Kohli & Passegue, [2014](#embj2018100409-bib-0019){ref-type="ref"}). Despite these advances, however, many of the molecular pathways and mechanisms that regulate the self‐renewal, survival, expansion, and regenerative functions of blood‐forming stem cells remain unknown. Improved understanding of the molecular machinery that determines HSC function will aid the development of innovative strategies to expand HSCs *ex vivo* and to prevent their involvement in hematopoietic cancers.

Protein kinase δ (*PKCδ*) is a member of the novel subclass of PKC serine/threonine kinase isoforms and has been implicated in regulating key cellular processes including proliferation, apoptosis, differentiation, and metabolism via its role in diverse downstream signal transduction pathways (Basu & Pal, [2010](#embj2018100409-bib-0001){ref-type="ref"}; Bezy *et al*, [2011](#embj2018100409-bib-0002){ref-type="ref"}). Although the role of *PKCδ* in apoptosis appears to be stimulus‐ and context‐dependent, in most cases, overexpression or activation of *PKCδ* induces apoptosis (Basu & Pal, [2010](#embj2018100409-bib-0001){ref-type="ref"}). PKCδ can be activated by diacyl glycerol (DAG) and phorbol esters (such as PMA) (Basu & Pal, [2010](#embj2018100409-bib-0001){ref-type="ref"}), which triggers a pro‐apoptotic signaling cascade that may include proteolytic activation and translocation of PKCδ to the mitochondria (Limnander *et al*, [2011](#embj2018100409-bib-0024){ref-type="ref"}).

PKCδ is widely expressed in the mouse and human hematopoietic systems (Limnander *et al*, [2011](#embj2018100409-bib-0024){ref-type="ref"}), and one of its best‐studied functions in hematopoiesis is in B‐cell signaling, where PKCδ deficiency enhances B‐cell proliferation and leads to autoimmunity in mice and man (Miyamoto *et al*, [2002](#embj2018100409-bib-0028){ref-type="ref"}; Guo *et al*, [2004](#embj2018100409-bib-0010){ref-type="ref"}; Limnander *et al*, [2011](#embj2018100409-bib-0024){ref-type="ref"}). However, the role of PKCδ in regulating more primitive hematopoietic precursors, including blood‐forming hematopoietic stem and progenitor cells (HSPCs), has not been interrogated. Given the established role of PKCδ in regulating cell survival, proliferation, and metabolism (Basu & Pal, [2010](#embj2018100409-bib-0001){ref-type="ref"}; Bezy *et al*, [2011](#embj2018100409-bib-0002){ref-type="ref"}), and the fact that perturbations in cell survival, proliferation, or metabolic signals can disrupt the functional integrity of HSPCs, we hypothesized that PKCδ may play a role in regulating HSPC homeostasis. Here, we test this hypothesis using *in vivo* and *in vitro* approaches and demonstrate that PKCδ restricts HSPC number and function in the steady‐state and during hematopoietic stress conditions. *PKCδ* ^−/−^ mice showed increased numbers of HSPCs in the bone marrow and better competence in bone marrow transplantation assays. Mechanistically, these phenotypes could be attributed to accelerated cell cycle progression and reduced apoptosis in *PKCδ‐*deficient HSPCs. Finally, we found that *PKCδ*‐deficient HSPCs display enhanced mitochondrial activity and oxidative phosphorylation. Our results indicate a pivotal role for PKCδ in the regulation of HSPC proliferation and apoptosis and identify PKCδ as a critical rheostat controlling HSPC expansion. Thus, targeting of PKCδ may represent an attractive strategy to stimulate *ex vivo* expansion of HSPCs and enhance hematopoietic recovery following HSPC transplantation.

Results {#embj2018100409-sec-0002}
=======

PKCδ deficiency expands the primitive HSC pool *in vivo* {#embj2018100409-sec-0003}
--------------------------------------------------------

To investigate the role of PKCδ in hematopoietic homeostasis, we first examined its expression during steady‐state blood cell differentiation in the bone marrow of wild‐type mice. Real‐time PCR analysis of PKCδ mRNA in FACS‐sorted Lineage negative (Lin^−^), Lin^−^Sca1^+^c‐Kit^+^ (LSK) cells, LT‐HSC, ST‐HSC, MPP, myeloid progenitors (GMP, CMP, MEP), and common lymphoid progenitor (CLP) subsets revealed that *PKCδ* is expressed at variable levels by all HSPC populations, with the highest expression in CLP, LT‐HSC, and MPPs. The lowest levels of PKCδ expression were observed in megakaryocyte‐erythroid progenitors (MEP) (Fig [1](#embj2018100409-fig-0001){ref-type="fig"}A). This expression pattern suggests that PKCδ functions in primitive LT‐HSCs, as well as in multiple other stages of hematopoiesis.

![PKCδ restricts HSPC pool size in the bone marrow\
AQuantitative real‐time PCR analysis of *PKCδ* mRNA levels in FACS‐sorted Lin^−^, LT‐HSC, ST‐HSC, MPP, L^−^S^−^K^+^, GMP, CMP, MEP, and CLP subsets from C56BL/6 wild‐type (6‐ to 9‐week‐old) mice bone marrow. Levels of *PKCδ* expression were normalized to an internal control gene (β‐actin). Expression of *PKCδ* is shown relative to Lineage negative (Lin^−^) cells whose expression was arbitrarily set to 1 (*n = *4 mice analyzed for each population).B, C(B) FACS plots depict the percentage of live, Lin^−^Sca1^+^c‐Kit^+^ (LSK) (left panel), and primitive CD34^−^Flt3^−^, CD34^+^Flt3^−^, and CD34^+^Flt3^+^ HSPCs among LSK cells (right panel). (C) Bar charts show the average frequency (left) and absolute number (right) ± SEM of the indicated populations, analyzed from 2 femurs and 2 tibias per mouse (*n = *10 mice analyzed for each genotype).DFACS plots show percentages of "SLAM code" based stem and progenitor cells in the LSK population. Bar graphs show the average frequency (left) and absolute numbers (right) ± SEM of LT‐HSC per 2 femurs and 2 tibias. (*n = *10 mice analyzed for each genotype).EFACS plots illustrate gating and frequencies of myeloid progenitors (MP), granulocyte--monocyte progenitor (GMP), common myeloid progenitor (CMP), and megakaryocyte--erythroid progenitor (MEP) population. Bar graphs show the frequencies (left) and absolute numbers (right) of L^−^S^−^K^+^ MP and GMP, CMP, and MEP populations in the BM of WT (*n = *12) and PKCδ KO (*n = *12).FFACS plots illustrate the gating and percentages of common lymphoid progenitors (CLP). Bar graph shows the absolute number of CLPs per 2 femurs and 2 tibias (*n = *5 mice for each genotype).GFACS plots illustrate the percentages of uncommitted lymphoid progenitors (Lin^−^ IL‐7Rα^+^Flt3^+^Ly‐6D^−^) and B lymphoid progenitors (BLP). Bar graph represents the average frequencies of CLPs, BLP, and uncommitted lymphoid progenitors in total BM (*n = *5 mice per genotype).HLimiting dilution analysis (LDA) demonstrates an increased frequency of long‐term repopulating HSCs in PKCδ KO BM (solid red lines) compared with WT BM (black solid lines). Engraftment data shown at 14 weeks post‐BMT. Plots depict the percentages of recipient mice containing \< 1% CD45.2^+^ blood nucleated cells. Dotted lines represent the 95% confidence interval of the same (*P* = 0.0005).Data information: All data are presented as mean ± SEM. \**P* \< 0.05; \*\**P* \< 0.01, and \*\*\**P* \< 0.001 by with one‐way ANOVAs with Sidak\'s multiple comparisons test (A) or two‐tailed Student\'s unpaired *t*‐test (C‐G) analysis for comparison of WT to PKCδ KO mice. Overall, test for differences in stem cell frequencies between WT to PKCδ KO mice was determined with likelihood ratio test of single‐hit model (H).](EMBJ-37-e100409-g002){#embj2018100409-fig-0001}

As an initial approach to probe the importance of PKCδ signaling in bone marrow (BM) HSPCs, we exposed FACS‐purified wild‐type HSPCs to Indolactam V (Indo‐V), a non‐specific PKC isoform activator, or Mallotoxin (MTX, also called Rottlerin), a PKC inhibitor that shows some selectivity for PKCδ when used at lower concentrations (3--5 μM) (Gschwendt *et al*, [1994](#embj2018100409-bib-0009){ref-type="ref"}). Interestingly, Indo‐V accelerated acquisition of lineage markers and depletion of primitive LSK HSPCs from the culture, whereas MTX increased the relative proportion of Lin^−^ cells and LSK cells (Fig [EV1](#embj2018100409-fig-0001ev){ref-type="fig"}A--C). Consistent with enhanced maintenance of more primitive HSPCs in PKC‐inhibited cultures, transplantation of MTX‐treated HSPCs resulted in 2‐ to 3‐fold higher contributions to mature hematopoietic lineages than transplantation of untreated control cells (Fig [EV1](#embj2018100409-fig-0001ev){ref-type="fig"}D), although levels of engraftment were generally low in both experimental groups. These data suggest that the PKC pathway plays a role in regulating the number and/or function of hematopoietic reconstituting cells. To evaluate this possibility more specifically, we next determined the frequencies and absolute numbers of BM HSPCs in germline PKCδ knockout mice (Bezy *et al*, [2011](#embj2018100409-bib-0002){ref-type="ref"}), which allow for highly specific inactivation of PKCδ *in vivo*. PKCδ knockout mice displayed a slight but significant increase in BM cellularity ([Appendix Fig S1A](#embj2018100409-sup-0001){ref-type="supplementary-material"}), and immunophenotypic analysis further revealed an increase in the frequency and absolute numbers (\~2‐ to 3‐fold increase) of LSK cells in the BM of PKCδ*‐*deficient mice (Fig [1](#embj2018100409-fig-0001){ref-type="fig"}B, left plots). This expansion of LSK cells was unique to the *PKCδ*‐deficient BM, as analysis of e14.5 fetal livers revealed equivalent frequencies of LSK cells in *PKCδ* ^−/−^, *PKC* ^−/−^, and *PKCδ* ^+/+^ mice ([Appendix Fig S1B](#embj2018100409-sup-0001){ref-type="supplementary-material"}). More comprehensive analysis of the adult LSK compartment using Flt3‐ and CD34‐based immunophenotypic fractionation indicated a significant increase in the frequency and absolute numbers of LT‐HSC (CD34^−^Flt3^−^LSK), ST‐HSC (CD34^−^Flt3^−^LSK), and MPP (CD34^+^Flt3^+^LSK) (Fig [1](#embj2018100409-fig-0001){ref-type="fig"}B and C). Consistent with this, "SLAM code" based analysis (Kiel *et al*, [2005](#embj2018100409-bib-0018){ref-type="ref"}) of BM LSK cells confirmed an \~3‐fold increase in the frequency and numbers of LT‐HSC (CD150^+^CD48^−^LSK) in PKCδ‐deficient mice compared with wild‐type littermates (Fig [1](#embj2018100409-fig-0001){ref-type="fig"}D).

![Pharmacological modulation of PKCδ activity preserves HSPC activity *in vitro*\
A, BOne hundred HSCs were sorted from WT mice and cultured in 96‐well (U‐bottom) plates in triplicate in the presence of mSCF (20 ng/ml) and mTPO (20 ng/ml) and with or without Mallotoxin (MTX, 5 μM) or Indolactam V (Indo‐V, 10 μM) for indicated time. (A) FACS histograms and (B) bar graph show the percentage of Lin‐ cells (pre‐gated on live cells).CAt the indicated time of culture, cells were analyzed for LSK phenotype. Representative FACS plots showing the percentage of cells retaining LSK phenotype. Data are representative of two independent experiments (*n = *5 mice total per treatment group).DSchematic of competitive reconstitution analysis of MTX‐treated WT HSPCs. After 13 days in culture, cells were transplanted into recipient mice along with 1 × 10^6^ competitive total BM cells (CD45.1^+^). Percentage of total donor‐derived cells (CD45.2^+^), B cells (B220^+^), and myeloid cells (CD11b^+^ Gr1^+^) in the peripheral blood was analyzed at indicated time (*n = *6 mice per condition).Data information: All data shown as mean ± SEM. \**P* \< 0.05 and \*\**P* \< 0.01 by repeated measures one‐way ANOVA analysis with Bonferroni posttest.](EMBJ-37-e100409-g003){#embj2018100409-fig-0001ev}

Intriguingly, despite an increased frequency of primitive HSPCs in the BM of *PKCδ* ^−/−^ mice, analysis of myeloid progenitors (Lin^−^Sca1^−^kit^+^, MyP) and further fractionation of these heterogeneous cell types into GMP (Lin^−^Sca1^−^kit^+^CD34^+^FcεRγIII/II^+^), CMP (Lin^−^Sca1^−^kit^+^CD34^+^FcεRγIII/Il^lo^), and MEP (Lin^−^Sca1^−^kit^+^CD34^+^ FcεRγIII/II^+^) revealed that the frequencies of these subsets were generally unchanged, with a modest and selective decrease in frequency and absolute number of CMPs in the absence of *PKCδ* (Fig [1](#embj2018100409-fig-0001){ref-type="fig"}E). Consistent with these observations, *PKCδ* ^−/−^ BM cells showed a significantly increased frequency of *in vitro* colony‐forming cells (CFU‐C), measured at day 12 ([Appendix Fig S1C](#embj2018100409-sup-0001){ref-type="supplementary-material"}). Furthermore, *in vivo* colony‐forming unit‐spleen (CFU‐S) assays (Zhang *et al*, [2009](#embj2018100409-bib-0048){ref-type="ref"}), in which transplanted BM cells form hematopoietic colonies in recipient spleens, revealed equivalent numbers of colonies at day 8 after transplantation (CFU‐S~8~) and significantly higher numbers of colonies at day 13 (CFU‐S~13~) in recipients of KO BM ([Appendix Fig S1D](#embj2018100409-sup-0001){ref-type="supplementary-material"}). The frequencies of mature circulating myeloid and erythroid cells were not detectably perturbed in PKCδ‐deficient mice ([Table EV1](#embj2018100409-sup-0003){ref-type="supplementary-material"}).

In both mice and humans, PKCδ deficiency causes increased B‐cell proliferation and autoimmunity (Miyamoto *et al*, [2002](#embj2018100409-bib-0028){ref-type="ref"}; Kuehn *et al*, [2013](#embj2018100409-bib-0020){ref-type="ref"}). To determine whether this B‐cell hyperproliferative phenotype due to PKCδ deficiency may be evident at the progenitor stage, we measured the frequency and absolute numbers of common lymphoid progenitors (CLP, Lin^−^IL‐7Rα^+^Flt3^+^) and B lineage‐committed progenitors (BLPs, Lin^−^IL7‐Rα^+^Flt3^+^Ly‐6D^+^). Our analyses indicated similar frequencies and absolute numbers of CLPs and BLPs in the bone marrow of *PKCδ* ^+/+^ and *PKCδ* ^−/−^ mice (Fig [1](#embj2018100409-fig-0001){ref-type="fig"}F and G). Finally, to assess whether the increase in phenotypic HSCs in PKCδ‐deficient mice correlated with an increase in hematopoietic reconstituting cells, we performed limit dilution transplantation assays, in which graded numbers of *PKCδ* ^+/+^ or *PKCδ* ^−/−^ BM cells (CD45.2^+^) were mixed with a fixed number (2.5 × 10^5^) of recipient type BM cells (CD45.1^+^) and transplanted into lethally irradiated CD45.1 recipients. These studies revealed a significant increase in reconstituting cell frequency in *PKCδ* ^−/−^ as compared to *PKCδ* ^+/+^ BM cells (1 in 11,042 versus 1 in 50,364, *P = *0.0005, Fig [1](#embj2018100409-fig-0001){ref-type="fig"}H). Thus, deficiency of PKCδ results in a significant immunophenotypic expansion of the LT‐HSC, ST‐HSC, and MPP populations, an increase in primitive CFU‐S~13~ activity, and an almost four‐fold increase in the frequency of hematopoietic reconstituting cells as assayed by limit dilution engraftment studies. Collectively, these data suggest that functional PKCδ acts normally to limit expansion of the phenotypic and functional pool of HSPCs in adult bone marrow.

Accelerated proliferation and reduced apoptosis of PKCδ‐deficient HSPCs *in vivo* {#embj2018100409-sec-0004}
---------------------------------------------------------------------------------

We next investigated the underlying mechanisms that may account for the increased HSPC pool size in the BM of adult PKCδ‐deficient mice. Because PKCδ has been implicated in regulating cell cycle and apoptosis in various cell lines (Basu & Pal, [2010](#embj2018100409-bib-0001){ref-type="ref"}), and loss of PKCδ is associated with a dramatic increase in HSPCs *in vivo* (Fig [1](#embj2018100409-fig-0001){ref-type="fig"}), we hypothesized that increased HSPC numbers in PKCδ‐deficient BM could reflect an altered proliferation rate or decreased spontaneous cell death *in vivo*. To test this hypothesis, we examined possible changes in the cell cycle status of HSPCs during steady‐state hematopoiesis using intracellular staining with Ki67/Hoechst. These analyses revealed a significant increase (two‐fold) in the percentage of cycling (S/G2/M, identified as Ki67^hi^ Hoechst^hi^) HSPCs and early progenitors in *PKCδ‐*knockout mice as compared to WT controls (Fig [2](#embj2018100409-fig-0002){ref-type="fig"}A). PKCδ‐KO HSCs further exhibited a substantial decrease in the quiescent G0 phase (Ki67^low^ Hoechst^low^) and a concomitant increase in the fraction of cells in the active G1 phase (Ki67^+^Hoechst^low^) of cell cycle. Next, we performed a short‐term (20 hr) *in vivo* BrdU labeling assay to quantify the frequency of actively proliferating cells in HSPC subsets (Fig [2](#embj2018100409-fig-0002){ref-type="fig"}B). In line with our findings using combinatorial Ki67/Hoechst staining, BrdU incorporation revealed an approximately 2.5‐fold higher rate of BrdU incorporation in LT‐HSCs from KO mice compared to *WT* controls (\~20% versus 7.5%, Fig [2](#embj2018100409-fig-0002){ref-type="fig"}C). A moderate increase in BrdU^+^ cells was also observed in *PKCδ*‐deficient ST‐HSCs and MPPs, but not among myeloid progenitor stages (Fig [2](#embj2018100409-fig-0002){ref-type="fig"}B and C). These data suggest that loss of *PKCδ* activates cell cycle progression of primitive HSPCs, which in turn leads to their expansion.

![Accelerated proliferation and reduced apoptosis in subsets of PKCδ‐deficient HSPCs\
Representative FACS profiles of HSPC cell cycle analysis using combinatorial staining for Ki67 and Hoechst 33342. Bar charts depict the average percentage of cells in each phase of the cell cycle for each LSK subset from WT (*n = *6) and PKCδ KO (*n = *7) mice. Data compiled from two independent experiments.FACS profiles of indicated BM subsets from WT and *PKCδ* KO mice 20 hr after BrdU injection.Average percentages of cells in each phase of the cell cycle phases for each of the indicated HSPC subsets from WT and PKCδ KO mice. Data are pooled from two independent experiments (totaling *n = *6--7 mice per genotype).Representative FACS plots and summary of FACS data analyzing the frequency of apoptotic HSPC cells using co‐staining for Annexin V and 7‐AAD (WT and *PKCδ* ^−/−^ (*n = *7 per genotype).Data information: All data are presented as mean ± SEM, \**P* \< 0.05 and \*\**P* \< 0.001, with significance determined by two‐tailed Student\'s unpaired *t*‐test analysis.](EMBJ-37-e100409-g004){#embj2018100409-fig-0002}

We next assessed the frequencies of apoptotic cells among HSPC subsets using Annexin V/7‐AAD staining. Percentages of Annexin V^+^/7‐AAD^−^ (apoptotic) LT‐HSCs were not substantially different between WT and *PKCδ* ^−/−^ mice; however, ST‐HSCs, MPPs, and myeloid progenitors from *PKCδ* ^−/−^ mice exhibited a significantly lower rate (two‐fold reduction) of spontaneous cell death as compared to their WT counterparts (Fig [2](#embj2018100409-fig-0002){ref-type="fig"}D). These data suggest that loss of PKCδ signaling in progenitor cells downstream of LT‐HSCs exerts a protective role that reduces apoptotic rate. Collectively, these results indicate that the expansion of the primitive HSPC compartment apparent in PKCδ‐deficient BM reflects alterations in both cell cycle progression and survival of HSPCs, with differential impact on distinct subsets of multi‐potent and oligopotent progenitors.

Loss of PKCδ enhances competitive repopulation capacity {#embj2018100409-sec-0005}
-------------------------------------------------------

The accumulation of primitive stem and progenitor cells in *PKCδ‐*deficient mice BM could result from loss of *PKCδ* activity within HSPCs themselves or from defects in microenvironmental cues arising due to loss of *PKCδ* in hematopoietic or non‐hematopoietic lineages that could indirectly affect their numbers. To distinguish hematopoietic system intrinsic versus extrinsic effects of PKCδ deficiency on HSPC function, we performed competitive BM transplants, in which total BM cells from WT or *PKCδ* ^−/−^ mice were transplanted into lethally irradiated congenic WT mice (CD45.1^+^) along with equal numbers of recipient type (CD45.1^+^) whole BM cells (Fig [3](#embj2018100409-fig-0003){ref-type="fig"}A). Analysis of peripheral blood chimerism in primary recipients revealed a slight but significant increase in engraftment of CD45.2^+^ hematopoietic lineages, with particular enhancement of B‐cell (B220^+^) (Limnander *et al*, [2011](#embj2018100409-bib-0024){ref-type="ref"}) and myeloid (Gr1^+^Mac‐1^+^) reconstitution, in mice receiving BM cells from *PKCδ* ^−/−^ as compared to control mice (Fig [3](#embj2018100409-fig-0003){ref-type="fig"}B).

![Loss of PKCδ enhances competitive repopulation and self‐renewal of HSPCs *in vivo* without exhaustion\
Schematic of competitive BM transplantation assay.Percent of total donor‐derived, hematopoietic cells (CD45.2^+^), B cells (B220^+^), myeloid cells (CD11b^+^Gr1^+^), and T cells (CD3^+^) in the peripheral blood (PB) of recipient mice, as determined by FACS at the indicated time points. The statistical significance of differences was determined using two‐way ANOVAs with Holm--Sidak\'s multiple comparisons tests (*n = *8 recipients per genotype in each experiment).Percent donor‐derived HSPCs in the BM of secondary (left) and tertiary (right) recipients of WT or *PKCδ* ^−/−^ marrow. Data are compiled from two independent experiments (*n = *8 recipients per genotype).Data information: All data are presented as mean ± SD. \**P* \< 0.05, \*\**P* \< 0.001, with significance determined by repeated measures two‐way ANOVA analysis with Sidak\'s multiple comparison tests for comparison of recipients of WT and PKCδ KO marrow at each time point and for each cell population.](EMBJ-37-e100409-g006){#embj2018100409-fig-0003}

To test the long‐term self‐renewal and differentiation capacities of *PKCδ* ^−/−^ HSPCs, we next conducted serial transplantation studies, which impose overt proliferative stress on HSCs (Min *et al*, [2008](#embj2018100409-bib-0027){ref-type="ref"}; Pietras *et al*, [2014](#embj2018100409-bib-0034){ref-type="ref"}; Rao *et al*, [2015](#embj2018100409-bib-0035){ref-type="ref"}). Defects in regulating self‐renewal capacity or aberrant cell cycle activity can lead to HSC exhaustion in this setting. Total BM cells were harvested from primary recipients 20 weeks after initial transplantation and infused into lethally irradiated secondary recipients. Hematopoietic reconstitution was monitored by staining of peripheral blood cells sampled over 16 weeks after transplant (Fig [3](#embj2018100409-fig-0003){ref-type="fig"}A and B). Then, at 16 weeks after secondary transplant, total BM cells were harvested again to assess reconstitution potential in tertiary recipients (Fig [3](#embj2018100409-fig-0003){ref-type="fig"}A and B). Although accelerated cycling is frequently associated with progressive exhaustion of HSCs (Yilmaz *et al*, [2006](#embj2018100409-bib-0045){ref-type="ref"}; Min *et al*, [2008](#embj2018100409-bib-0027){ref-type="ref"}; Khandanpour *et al*, [2010](#embj2018100409-bib-0017){ref-type="ref"}; Pietras *et al*, [2011](#embj2018100409-bib-0033){ref-type="ref"}), mice receiving BM cells from *PKCδ* ^−/−^ mice showed enhanced reconstitution by *PKCδ* ^−/−^ cells in both the myeloid and B‐cell compartments, as compared to control BM recipients, in both secondary and tertiary recipients (Fig [3](#embj2018100409-fig-0003){ref-type="fig"}B). Interestingly, *PKCδ* ^−/−^ T‐cell reconstitution efficiency was enhanced only in tertiary, and not primary or secondary, recipients (Fig [3](#embj2018100409-fig-0003){ref-type="fig"}B). To assess whether the enhanced hematopoietic reconstitution potential of *PKCδ* ^−/−^ BM reflected the higher frequency of HSPCs in these animals, we measured the frequency of donor‐derived (CD45.2^+^) HSPCs in secondary and tertiary recipients. Both the frequency and number of donor‐derived primitive HSPCs were increased in recipients of PKCδ‐deficient as compared to control marrow (Fig [3](#embj2018100409-fig-0003){ref-type="fig"}C). Interestingly, competitive transplantation experiments using purified HSCs from *PKCδ* ^+/+^ or *PKCδ* ^−/−^ mice ([Appendix Fig S1E](#embj2018100409-sup-0001){ref-type="supplementary-material"}) showed that, with transfer of equal cell numbers, *PKCδ* ^−/−^ HSCs reconstitute irradiated recipients with equal efficiency compared to *PKCδ* ^+/+^ HSCs ([Appendix Fig S1F](#embj2018100409-sup-0001){ref-type="supplementary-material"}). Thus, on a per stem cell level, *PKCδ* ^−/−^ HSCs are equipotent in reconstituting irradiated recipients, and the greater reconstitution levels seen with transfer of whole bone marrow likely reflects the higher numbers of primitive HSPCs in the marrow of *PKCδ* ^−/−^ as compared to *PKCδ* ^+/+^ mice. Altogether, these data indicate that, despite their increased cell cycle activity, PKCδ‐deficient HSPCs are not inferior to wild‐type HSPCs and support augmented long‐term, multi‐lineage hematopoietic reconstitution in bone marrow transplant and serial transplantation settings.

Increase in immunophenotypic and functional HSPCs upon hematopoietic‐specific deletion of PKCδ {#embj2018100409-sec-0006}
----------------------------------------------------------------------------------------------

The competitive transplantation assays described above strongly suggest that the accumulation of primitive stem and progenitor cells in PKCδ‐deficient mice is attributable to changes within the hematopoietic system itself. To eliminate potential effects of compensatory signals arising from loss of PKCδ in non‐hematopoietic cells prior to hematopoietic cell transplantation, we generated a lineage‐specific PKCδ knockout mouse by crossing *PKCδ* ^*fl*/*fl*^ mice (Bezy *et al*, [2011](#embj2018100409-bib-0002){ref-type="ref"}) with mice carrying an Mx1‐Cre transgene (Kuhn *et al*, [1995](#embj2018100409-bib-0021){ref-type="ref"}). This model allows for pan‐hematopoietic interferon or polyinosine/polycytosine (pIpC)‐inducible PKCδ allele excision and also drives allelic excision in a subset of stromal cells (Kuhn *et al*, [1995](#embj2018100409-bib-0021){ref-type="ref"}; Park *et al*, [2012](#embj2018100409-bib-0030){ref-type="ref"}). Administration of five doses of pIpC at 4--6 weeks after birth led to near complete absence of PKCδ protein in the Lin^−^ c‐Kit^+^ subset of BM cells in *PKCδ* ^*fl*/*fl*^ *;Mx‐1Cre* ^+^ mice, as compared to *PKCδ* ^*fl*/*fl*^; controls lacking the *Mx‐1Cre* allele (*PKCδ* ^*fl*/*fl*^ *;Mx‐1Cre* ^−^ mice) (Fig [EV2](#embj2018100409-fig-0002ev){ref-type="fig"}A). Moreover, consistent with previous reports evaluating germline‐deficient PKCδ KO mice (Mecklenbrauker *et al*, [2002](#embj2018100409-bib-0026){ref-type="ref"}; Miyamoto *et al*, [2002](#embj2018100409-bib-0028){ref-type="ref"}; Limnander *et al*, [2011](#embj2018100409-bib-0024){ref-type="ref"}), we observed enlarged lymph nodes and a significantly expanded peripheral B220^+^ B‐cell compartment at 24 weeks after pIpC induction in *PKCδ* ^*fl*/*fl*^;*Mx‐1Cre* ^+^ mice (Fig [EV2](#embj2018100409-fig-0002ev){ref-type="fig"}B). These PKCδ*‐*deleted mice are hereafter referred to as *PKC*δ^*Δ*/*Δ*^ (*cKO*) and control mice, treated with pIpC but lacking the Mx1‐Cre allele, are referred to as *PKCδ* ^*fl*/*fl*^.

![Characterization of hematopoietic stem and progenitor cell subsets in the BM of WT and PKCδ *c*KO mice\
AExperimental design. Representative Western blot analysis for detecting *PKCδ* protein in Lin^−^Kit^+^ BM cells from indicated mice at 8‐week post‐pIpC treatment shows absence of *PKCδ* protein in cKO cells.BFACS histograms show the frequency of B220^+^ cells in spleen and lymph nodes of cKO mice at 24‐week post‐pIpC treatment (*n = *6--8 mice per genotype).CIncreased frequency of HSPCs in the BM of *control* and *cKO* mice at 4--8 or 20--24 weeks after pIpC treatment (*n = *8--9 mice per genotype and time point).D, EFrequency of HSCs (HSC‐SLAM) (D), and myeloid progenitor subsets (E) in the BM of *control* and *cKO* mice at 4--8 and 20--24 weeks after pIpC treatment (*n = *8--9 mice per genotype and time point).FFrequency of common lymphoid progenitors (CLPs) in the BM of *control* and *cKO* mice at 4--8 and 20--24 weeks after pIpC treatment (*n = *6 mice per genotype and time point).GRepresentative FACS plots show the gating strategy of MkP, Pre‐MegE, MkP, Pre‐CFU‐E, and CFU‐E/Pro‐E subpopulations in the BM of *WT* and *cKO* mice at 24 weeks after pIpC treatment.HFrequencies of indicated subsets in the total BM (*n = *6 mice per genotype).Data information: All data are presented as mean ± SEM, \**P* \< 0.05, \*\*\**P* \< 0.01, and \*\*\**P* \< 0.001, by repeated measures two‐way ANOVA analysis with Sidak\'s multiple comparison tests (B, D, and F) or by two‐tailed Student\'s unpaired *t*‐test analysis (C, E, and H).](EMBJ-37-e100409-g005){#embj2018100409-fig-0002ev}

Analysis of *PKC*δ^*Δ*/*Δ*^ (*cKO*) and *PKCδ* ^*fl*/*fl*^ mice at 4--8 weeks after the last pIpC injection revealed that acute deletion of *PKCδ* in hematopoietic and stromal lineages produced a significant increase in the frequency and number of Lin^−^ cells in the BM, but did not alter total BM cellularity or circulating mature blood lineages ([Table EV2](#embj2018100409-sup-0004){ref-type="supplementary-material"}). These results contrast with observations in the full body *PKCδ* knockout mice, where bone marrow cellularity showed a slight, but consistent increase ([Appendix Fig S1A](#embj2018100409-sup-0001){ref-type="supplementary-material"}), possibly reflecting subtle effects of *PKCδ* loss in non‐hematopoietic cell types. Analysis of the Lin^−^ compartment in *cKO* BM revealed a 3‐ to 4‐fold increase in the absolute number and frequency of primitive HSPCs as compared with *PKCδ* ^*fl*/*fl*^ controls (Figs [4](#embj2018100409-fig-0004){ref-type="fig"}A and B, and [EV2](#embj2018100409-fig-0002ev){ref-type="fig"}C), recapitulating results obtained with germline‐deficient PKCδ^−/−^ BM (Fig [1](#embj2018100409-fig-0001){ref-type="fig"}B--D) and further confirming a role for PKCδ in regulation of HSPC pool size in adult BM.

![Augmented HSPC pool size following loss of PKCδ in hematopoietic and stromal cells\
AExperimental design for pIpC treatment and analysis of *PKCδ* ^*fl*/*fl*^ */Mx‐1Cre* ^−^ (*PKCδ* ^*fl*/*fl*^) and *PKCδ* ^*fl*/*fl*^/*Mx‐1Cre* ^+^ (*PKCδ* ^*Δ*/*Δ*^, cKO) mice.B, CRepresentative FACS plots of *PKCδ* ^*fl*/*fl*^ and *cKO* BM 4--8 weeks (B) and 20--24 weeks (C) after pIpC treatment. Numbers in plot indicate the absolute numbers of the indicated subset within the gated population (*n = *8--9 mice per genotype and time point).DSchematic of competitive BM transplants. Total BM cells from either *PKCδ* ^fl/fl^/*Mx‐1Cre* ^−^ (control) or *PKCδ* ^fl/fl^/*Mx‐1Cre* ^+^ mice were injected together with recipient type (CD45.1) BM cells (1:1) into lethally irradiated CD45.1 mice prior to pIpC treatment. Two months after transplant, both groups of mice received five doses of pIpC. Chimeras were analyzed at 16 weeks after the last pIpC injection.E, F(E) FACS plots show contribution of donor‐derived (CD45.2^+^) HSPCs in recipient BM (E). Calculated absolute numbers of donor‐derived HSPC subsets in transplanted mice (F) (total of *n = *7--8 mice per genotype).GAverage percentage BrdU^+^ HPSCs (3 days after BrdU injection into mice reconstituted 24 weeks previously with control or *cKO* marrow and injected 16 weeks previously with pIpC, see panel (D)) among donor‐derived LSK cells in the control and cKO chimeras BM.HPercentages of apoptotic cells (Annexin V^+^/7‐AAD^−^) in donor‐derived LSK cells in control and cKO chimera mouse BM at 24 weeks after transplant and 16 weeks after pIpC injection. Data are compiled from two independent experiments (total of *n = *7--8 mice per genotype).Data information: Data presented as mean ± SEM. \**P* \< 0.05, \*\**P* \< 0.005, and \*\*\**P* \< 0.001 by two‐tailed Student\'s unpaired *t*‐test analysis.](EMBJ-37-e100409-g008){#embj2018100409-fig-0004}

Strikingly, prolonged (20--24 weeks after the last pIpC injection) hematopoietic and stromal‐specific deletion of PKCδ further increased (\~5‐ to 10‐fold) the number of primitive HSPCs, including LT‐ and ST‐HSCs (Figs [4](#embj2018100409-fig-0004){ref-type="fig"}C and [EV2](#embj2018100409-fig-0002ev){ref-type="fig"}C and D). Likewise, "SLAM code" based analysis (Kiel *et al*, [2005](#embj2018100409-bib-0018){ref-type="ref"}) of BM LSK cells showed an \~five‐fold increase in LT‐HSC (CD150^+^CD48^−^LSK) frequency in cKO mice as compared to *PKCδ* ^*fl*/*fl*^ littermates (Fig [EV2](#embj2018100409-fig-0002ev){ref-type="fig"}D). Together with the transplant data discussed above (Fig [3](#embj2018100409-fig-0003){ref-type="fig"}), these results suggest that increased HSPC pool size in PKCδ‐deficient BM reflects loss of PKCδ activity within the hematopoietic system itself. Analysis of downstream lineage‐committed CMP and CLP populations revealed that while acute deletion of PKCδ causes a slight but significant reduction in the numbers of these progenitors at 4--8 weeks post‐induction, this reduction was not evident at later time points (20--24 weeks after PKCδ deletion; Fig [EV2](#embj2018100409-fig-0002ev){ref-type="fig"}E and F). However, prolonged deletion of PKCδ did produce a significant increase in the frequency and number of early megakaryocyte (Pre‐MegE and MkP) and erythroid progenitor subsets (Pre‐CFU/E and CFU‐E/Pro‐E) in cKO mice BM, albeit at variable levels (Fig [EV2](#embj2018100409-fig-0002ev){ref-type="fig"}G and H). Interestingly, this increase in Meg/E progenitors was not accompanied by an increase in the numbers of mature platelets or erythrocytes ([Table EV2](#embj2018100409-sup-0004){ref-type="supplementary-material"}). We also observed a 2‐ to 3‐fold increase in the frequency of LSK cells in the spleens of cKO mice (Fig [EV3](#embj2018100409-fig-0003ev){ref-type="fig"}A); however, HSPC expansion in the BM was not accompanied by an increase in their abundance in the peripheral blood (Fig [EV3](#embj2018100409-fig-0003ev){ref-type="fig"}B). Of note, despite dramatic expansion of the primitive HSPC pool, cKO mice did not show any signs of malignancy when followed up to 10 months after pIpC induction (data not shown). Collectively, these data suggest that hematopoietic deletion of PKCδ mirrors for the most part germline loss of this gene and leads to progressive accumulation of HSPCs in the BM with retention of relatively normal (with the exception of increased frequency of B‐cell lineages) hematopoietic differentiation capacity.

![Expanded HSPC pool size in PKCδ cKO mice\
Frequency of LSK cells in the spleen of *control* and *cKO* mice at 20--24 weeks after pIpC treatment (*n = *4--5 mice per genotype).Frequency of LSK cells in the peripheral blood of *control* and *cKO* mice at 20--24 weeks after pIpC treatment (*n = *4--5 mice per genotype).Representative FACS plots and bar graph show the mean percentage of apoptotic cells in the indicated HSPC subsets of *PKCδ* ^*fl*/*fl*^ (control) and *PKCδ* cKO BM at 8 weeks after pIpC treatment (*n = *7 mice per genotype).Cell cycle distribution of indicated HSPC subsets from *PKCδ* ^*fl*/*fl*^ (WT) and PKCδ cKO mice at 8 weeks after pIpC treatment (*n = *7 mice per genotype) as assessed by Ki67‐Hoechst staining.Short‐term BrdU incorporation assay. Bar graph shows the percentage of BrdU^+^ cells in each BM HSPC subsets of *PKCδ* ^*fl*/*fl*^ (control) and PKCδ cKO mice at 8 weeks after pIpC treatment (*n = *7 mice per genotype).Data information: All data are presented as mean ± SEM, \**P* \< 0.05, \*\*\**P* \< 0.01, and \*\*\**P* \< 0.001, by two‐tailed Student\'s unpaired *t*‐test analysis.](EMBJ-37-e100409-g007){#embj2018100409-fig-0003ev}

To determine whether increased HSPC pool size in the BM of PKCδ cKO mice reflected changes in HSPC survival and proliferation rate, as in germline *PKCδ* ^−/−^ mice (Figs [1](#embj2018100409-fig-0001){ref-type="fig"}, [2](#embj2018100409-fig-0002){ref-type="fig"}, [3](#embj2018100409-fig-0003){ref-type="fig"}), we measured the survival and proliferation of PKCδ cKO HSPCs using Annexin V and Ki67/Hoechst staining, respectively. HSPCs from cKO mice showed slightly lower rates of spontaneous apoptosis than HSPCs from *PKCδ* ^*fl*/*fl*^ animals, particularly in the LSK, ST‐HSC, and MPP compartments (Fig [EV3](#embj2018100409-fig-0003ev){ref-type="fig"}C), confirming a pro‐survival role for PKCδ in at least a subset of HSPCs. Cell cycle analysis by Ki67/Hoechst staining further revealed a significant increase in the percentage of HSPCs in G1 and S‐G2‐M phases of the cell cycle (Fig [EV3](#embj2018100409-fig-0003ev){ref-type="fig"}D), and an increased rate of labeling with BrdU (Fig [EV3](#embj2018100409-fig-0003ev){ref-type="fig"}E), in *cKO* as compared to control *PKCδ* ^*fl*/*fl*^ mice. These results, in a distinct genetic model of induced PKCδ deficiency, provide further evidence that *PKCδ* functions to restrict HSPC pool size by modulating rates of HSPC proliferation and apoptosis.

We next investigated the functional capacity of HSPCs from PKCδ cKO BM using competitive transplantation assays. To discriminate potentially confounding effects of PKCδ deletion in stromal niche cells (Kuhn *et al*, [1995](#embj2018100409-bib-0021){ref-type="ref"}; Park *et al*, [2012](#embj2018100409-bib-0030){ref-type="ref"}) or PKCδ function during HSPC homing, we transplanted "undeleted" CD45.2^+^ BM cells from *Mx1‐Cre;PKCδ* ^*fl*/*fl*^ mice, or control *PKCδ* ^*fl*/*fl*^ mice lacking *Mx1‐Cre*, competitively (1:1 with CD45.1^+^ cells) into lethally irradiated CD45.1^+^ recipients ([Appendix Fig S2A](#embj2018100409-sup-0001){ref-type="supplementary-material"}). At 8 weeks post‐transplant, CD45.2^+^ donor cell engraftment levels ranged from 60 to 70% and were indistinguishable for recipients of *Mx1‐Cre;PKCδ* ^*fl*/*fl*^ versus *PKCδ* ^*fl*/*fl*^ BM cells ([Appendix Fig S2B](#embj2018100409-sup-0001){ref-type="supplementary-material"}). Animals in both groups were then treated with pIpC, which induced PKCδ deletion in the *Mx1‐Cre;PKCδ* ^*fl*/*fl*^ recipients ([Appendix Fig S2B](#embj2018100409-sup-0001){ref-type="supplementary-material"}). Subsequent analysis of peripheral blood ([Appendix Fig S2](#embj2018100409-sup-0001){ref-type="supplementary-material"}) and BM HSPC chimerism (Fig [4](#embj2018100409-fig-0004){ref-type="fig"}D--H) at 8 and 16 weeks after pIpC induction revealed an increased representation of donor‐derived CD45.2^+^ peripheral blood leukocytes ([Appendix Fig S2B](#embj2018100409-sup-0001){ref-type="supplementary-material"}) and BM HSPCs (Fig [4](#embj2018100409-fig-0004){ref-type="fig"}E and F) in recipients in which *PKCδ* was deleted as compared to recipients receiving control BM cells. *cKO* HSPCs also exhibited an increase in BrdU incorporation (Fig [4](#embj2018100409-fig-0004){ref-type="fig"}G) and a decreased in the percent apoptotic cells (Fig [4](#embj2018100409-fig-0004){ref-type="fig"}H), recapitulating the phenotype observed in germline *PKCδ* cKO mice and suggesting that *PKCδ* negatively regulates HSPC pool size in a hematopoietic cell‐intrinsic manner, at least in part via effects on HSPC proliferation and survival.

Enhanced recovery from myeloablation in PKCδ‐deficient mice {#embj2018100409-sec-0007}
-----------------------------------------------------------

Collectively, our results in germline and inducible deletion models, coupled with analyses in competitive BM transplantation assays, strongly suggest that PKCδ negatively regulates HSC proliferation and survival during steady‐state hematopoiesis and restrains hematopoietic regeneration in transplant settings. To test the *in vivo* consequences of *PKCδ* deficiency under distinct hematopoietic stress conditions, we next treated *cKO* or control *PKCδ* ^*fl*/*fl*^ mice with 5‐fluorouracil (5‐FU, 150 mg/kg; Fig [5](#embj2018100409-fig-0005){ref-type="fig"}A), a cytotoxic drug that initiates a BM stress response by selectively killing actively cycling stem and progenitor cells. 5‐FU treatment causes a precipitous decline in the number of BM LSKs on days 2 through 7 (ablation phase) after treatment, which in turn leads to the reversible activation, rapid proliferation, and expansion of surviving quiescent HSCs from day 7 through 13 (recovery phase) (Schepers *et al*, [2012](#embj2018100409-bib-0038){ref-type="ref"}; Ehninger *et al*, [2014](#embj2018100409-bib-0007){ref-type="ref"}). When compared to control *PKCδ* ^*fl*/*fl*^ mice, PKCδ cKO mice displayed similar BM cell numbers and comparable kinetics of recovery of peripheral blood leukocytes, platelets, and red blood cells (RBC) after a single 5‐FU treatment (Fig [EV4](#embj2018100409-fig-0004ev){ref-type="fig"}A--C). Analysis of the BM HSPC compartment revealed similar depletion of LSK cells in *PKCδ* ^*fl*/*fl*^ and *cKO* mice at day 4 after 5‐FU treatment (Fig [5](#embj2018100409-fig-0005){ref-type="fig"}B); however, *cKO* mice showed accelerated recovery, with a significant increase in HSPC frequency at 13d (recovery phase) and 28d (the stage at which homeostasis is re‐established), as compared to control *PKCδ* ^*fl*/*fl*^ mice (Fig [5](#embj2018100409-fig-0005){ref-type="fig"}B and C). The spleen size was also increased in 5‐FU‐treated *cKO* mice as compared to controls at days 13 and 28 after 5‐FU treatment (Fig [EV4](#embj2018100409-fig-0004ev){ref-type="fig"}D), suggesting an enhancement of extra‐medullary hematopoiesis. Finally, consistent with analyses of PKCδ^−/−^ BM in the steady state, *PKCδ*‐deficient HSPCs in 5‐FU‐treated *cKO* mice displayed reduced apoptosis (Annexin V^−^/7‐AAD^−^ cells; Fig [5](#embj2018100409-fig-0005){ref-type="fig"}D) and an enhanced BrdU incorporation rate (Fig [5](#embj2018100409-fig-0005){ref-type="fig"}E) during recovery from myelosuppression.

![Accelerated recovery in PKCδ‐deficient mice after myeloablation by 5‐FU\
Experimental design. Thirty days after the last pIpC injection, *PKCδ* ^*fl*/*fl*^ and *PKCδ cKO* mice were treated with a single dose of 5‐FU (150 mg/kg, i.p.) and analyzed subsequently by FACS and BrdU incorporation studies.Kinetics of LSK cell recovery. Representative FACS profiles of BM LSK cells from WT and cKO mice at the indicated time points after 5‐FU treatment. Numbers in the contour plots indicate the percentages of LSK subsets among Lin^−^ live cells.Average absolute numbers of BM LSK cells at day 13 and day 28 after 5‐FU treatment. Data are pooled from two independent experiments (total of *n = *6--8 mice per time point and genotype).Quantification of apoptotic HSPCs at the indicted time points after 5‐FU treatment of control and *cKO* mice (*n = *6 per genotype).Representative FACS plots showing analysis of *in vivo* BrdU incorporation assays. Mice were received 2 mg of BrdU (i.p.) at d13 (left) or d28 (right) after 5‐FU treatment. 20 hours later, BrdU incorporation in BM LSK cells was assessed using anti‐BrdU antibodies. Bar chart at right indicates percent of BrdU^+^ LSK cells at d13 and d28 after 5‐FU treatment (*n = *6 per genotype and time point).Kaplan--Meier survival cures of control (*n = *12) and cKO (*n = *11) mice after sequential 5‐FU treatment. Mice were treated with 5‐FU (150 mg/kg, i.p.) once each week for 3 weeks. Arrows indicate time points of 5‐FU injection.Data information: Data presented as mean ± SEM. The statistical significance was assessed using repeated measures two‐way ANOVAs with Sidak\'s multiple comparisons tests (C) or by two‐tailed Student\'s unpaired *t*‐test analysis (D and E). \**P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001. Survival data (F) were analyzed using a log‐rank nonparametric test (Mantel‐Cox test) (*P = *0.0141).](EMBJ-37-e100409-g010){#embj2018100409-fig-0005}

![Hematopoietic recovery in *PKCδ* ^*fl*/*fl*^ and *PKCδ* cKO mice after 5‐FU treatment\
A, B(A) Experimental design, (B) kinetics of white blood cells (WBC), red blood cells (RBC), and platelet cell recovery in peripheral blood of WT and cKO mice after single dose of 5‐FU treatment (*n = *8--12 mice per genotype).CRepresentative hematoxylin--eosin (H&E)‐stained femur sections from indicated mice at day 4 of 13 and 28 after a single injection of 5‐FU treatment (bottom) (*n = *4--5 mice per time point for each genotype).DEnlarged spleen in *PKCδ* ^*Δ*/*Δ*^ *(*cKO*)* mice during recovery phase (d13) after 5‐FU treatment. Spleen size of WT and cKO mice at indicated time points after 5‐FU treatment.Data information: All data are presented as mean ± SEM, by repeated measures two‐way ANOVA analysis with Sidak\'s multiple comparison tests (B) for comparison of control and *PKCδ cKO* mice at each time point. \**P* \< 0.05.](EMBJ-37-e100409-g009){#embj2018100409-fig-0004ev}

Defects in cell cycle regulation of HSCs resulting in unscheduled proliferation can cause precocious exhaustion after repetitive myeloablation (Schepers *et al*, [2012](#embj2018100409-bib-0038){ref-type="ref"}; Ehninger *et al*, [2014](#embj2018100409-bib-0007){ref-type="ref"}). Considering PKCδ as a potential negative regulator of HSC proliferation, we next tested whether stem cell exhaustion might occur after repetitive myeloablative stress. Control and cKO mice were treated weekly with 5‐FU (150 mg/kg) for a total of 3 weeks and monitored for survival. Consistent with an increased fraction of proliferative HSCs, PKCδ cKO mice showed significantly enhanced sensitivity to repetitive 5‐FU treatment, with a median survival of 19 days as compared to 31 days for control mice (*P = *0.014) (Fig [5](#embj2018100409-fig-0005){ref-type="fig"}F).

Loss of PKCδ primes HSPC mitochondrial activity and energy metabolism {#embj2018100409-sec-0008}
---------------------------------------------------------------------

Emerging studies highlight the importance of metabolic state as a critical determinant regulating stem cell number and fate (Ito *et al*, [2012](#embj2018100409-bib-0014){ref-type="ref"}; Yu *et al*, [2013](#embj2018100409-bib-0046){ref-type="ref"}; Burgess *et al*, [2014](#embj2018100409-bib-0004){ref-type="ref"}; Kohli & Passegue, [2014](#embj2018100409-bib-0019){ref-type="ref"}; Wang *et al*, [2014](#embj2018100409-bib-0043){ref-type="ref"}). In adult BM, primitive HSCs are thought to reside in hypoxic regions and rely on low ATP generating glycolytic metabolism to maintain their quiescence. However, HSCs can switch to mitochondrial oxidative phosphorylation (OXPHOS) in response to differentiation signals, infection, or stress to fulfill the increased energy demands associated with differentiation (Yu *et al*, [2013](#embj2018100409-bib-0046){ref-type="ref"}; Kohli & Passegue, [2014](#embj2018100409-bib-0019){ref-type="ref"}). Since *PKCδ* has been implicated as a major upstream regulator of metabolic signaling in may cell types and tissues (Bezy *et al*, [2011](#embj2018100409-bib-0002){ref-type="ref"}), we investigated whether *PKCδ* might regulate HSPC proliferation and survival by influencing HSPC energy metabolism. We first measured mitochondrial oxygen consumption rate (OCR), in FACS‐purified HSPCs (LSK) using a Seahorse metabolic flux analyzer. *PKCδ*‐deleted HSPCs showed significantly elevated basal OCR as compared to controls (Fig [6](#embj2018100409-fig-0006){ref-type="fig"}A and B). PKCδ *cKO* HSPCs also showed a significant increase in maximal OCR (*P = *0.001) following FCCP treatment, which contributed to a substantial increase in spare respiratory capacity (SRC) (Fig [6](#embj2018100409-fig-0006){ref-type="fig"}C), an indicator of cellular fitness to respond to an energetic demand that has been associated with increased survival during stress (Maryanovich *et al*, [2015](#embj2018100409-bib-0025){ref-type="ref"}). Notably, this increased OCR did not reflect a change in glycolysis, as measurements of basal extracellular acidification rate (ECAR) were similar, while HSPCs from PKCδ *cKO* mice had higher levels of maximal ECAR after challenge with Oligomycin, a mitochondrial ATP synthase inhibitor that forces cells to utilize glucose via glycolysis rather than mitochondrial OXPHOS to meet energy demands (Fig [6](#embj2018100409-fig-0006){ref-type="fig"}D and E). Moreover, the increased metabolic activity of *cKO* HSPCs was not attributable to increased glucose uptake, as demonstrated by similar levels of fluorescent glucose (2‐NBDG) accumulation in HSPC subsets from *cKO* and control mice (Fig [EV5](#embj2018100409-fig-0005ev){ref-type="fig"}A), further indicating that increased energy production is largely accounted for by augmented OXPHOS. PKCδ *cKO* ST‐HSCs and MPPs also harbored significantly greater levels of ATP, although increased ATP levels were not observed in LT‐HSCs (Fig [6](#embj2018100409-fig-0006){ref-type="fig"}F).

![Increased mitochondrial number, activity, energy metabolism, and ROS levels in PKCδ‐deleted HSPCs\
AMitoStress test revealed increased oxygen consumption rates (OCR) in *PKCδ*‐deleted LSKs. BM LSK cells were sorted from WT and *PKCδ cKO* mice 12 weeks after pIpC treatment. OCR was measured at basal level and after sequential loading of ATP synthase inhibitor Oligomycin (350 nm), mitochondrial uncoupler, FCCP (10 μM), and electron transport chain inhibitor, Rotenone (1 μM) using Seahorse XF24 extracellular flux analyzer. Data are from three independent experiments (*n = *9 mice). In each experiment, bone marrow cells from identical genotypes (*n = *3 mice per genotype) were pooled and used for LSK cell sorting.B, C(B) Basal OCR was measured before inhibitors treatment (left); and the Maximal OCR capacity after FCCP treatment (right) (C). The spare respiratory capacity (SRC) of LSKs was calculated from the data shown in panel A (*n = *9 per genotype, from three independent experiments).D, E(D) Glycolysis stress test. Extracellular acidification rates (ECAR) of LSKs were measured at basal conditions (unbuffered assay medium without glucose) and after sequential loading of glucose (7.5 mM), Oligomycin (350 nm), and 2‐deoxyglucose (50 mM; 2DG, a glucose analog) (E). AUC of baseline ECAR levels (left), and glycolytic capacity (maximal ECAR) was calculated from the data shown in panel (D) (*n = *7--8 per genotype, from three independent experiments).FRelative ATP content in indicated HSPC subsets determined using an ATP assay kit (*n = *6 mice per genotype).GRepresentative FACS histograms of MitoTracker Green fluorescence intensity on indicated HSPC subsets from control and cKO mice. Relative MitoTracker Green mean fluorescence intensity (MFI) is quantified below for *n = *6 mice of each genotype.HRepresentative electron microscopy images (4,800× magnification) of control and *PKCδ cKO* HSPCs. Arrows indicate the mitochondria‐enriched regions (*n = *3 mice per genotype). Scale bar represents 500 nm.IROS levels in control and *PKCδ cKO* HSPCs as measured by FACS‐based CM‐H2DCFDA staining. Bar graph at right shows the relative CM‐H2DCFDA MFI. Data compiled from three independent experiments (*n = *6--8 per genotype).Data information: The statistical significance of difference was assessed using two‐tailed Student\'s unpaired *t*‐test analysis. All data are presented as mean ± SEM, \**P* \< 0.05, \*\**P* \< 0.001.](EMBJ-37-e100409-g012){#embj2018100409-fig-0006}

![Altered metabolic activity in PKCδ‐deficient cKO HSPCs is not due to impaired glucose uptake, and inhibiting ROS levels via NAC treatment does not rescue increased HSPC pool size in PKCδ‐deficient BM\
FACS‐sorted HSPC subsets were incubated with 2‐NBDG for the indicated time. Representative histograms of 2‐NBDG fluorescence at time indicated. Mean fluorescence intensity (MFI) of 2‐NBDG fluorescence at indicated time. Cells treated without 2‐NBDG used as controls. (*n = *5 mice per genotype, mean ± SEM).NAC treatment rescued the increased ROS levels in PKCδ‐deficient HSPCs. Representative histograms of CM‐H2DCFDA fluorescence.NAC treatment did not rescue increased HSPC pool size in *PKCδ*‐deficient BM. Bar graph represents HSPC frequency 8 weeks after NAC treatment. Untreated *PKCδ* ^*fl*/*fl*^ and *PKCδ* ^*Δ*/*Δ*^ *(*cKO*)* mice were used as controls (*n = *6 mice per genotype).Data information: All data are presented as mean ± SEM. Statistical significance was determined by repeated measures two‐way ANOVA analysis with Sidak\'s multiple comparison tests (A and C). \**P* \< 0.05 and \*\**P* \< 0.01.](EMBJ-37-e100409-g011){#embj2018100409-fig-0005ev}

Next, to assess whether the accelerated recovery of HSPCs in PKCδ *cKO* mice after 5‐FU treatment (Fig [5](#embj2018100409-fig-0005){ref-type="fig"}B and C) was associated with increased metabolic activity, we measured mitochondrial oxygen consumption rate (OCR) of HSPCs from mice given a single 5‐FU treatment 10 days prior (recovery phase). Consistent with analyses during steady state, HSPCs from myeloablated PKCδ *cKO* mice also showed a significant increase in both basal and maximal OCR, as well as ATP production compared to treated control cells ([Appendix Fig S3A and B](#embj2018100409-sup-0001){ref-type="supplementary-material"}), suggesting that PKCδ sets a threshold for metabolic activation of HSPCs during steady‐state and myeloablative regeneration.

To evaluate whether the increased mitochondrial function was associated with the changes in mitochondrial number and structure, we evaluated HSPC mitochondrial mass at 12--16 weeks after pIpC treatment using a mitochondrial membrane‐specific fluorescent dye, MitoTracker Green. MitoTracker Green mean fluorescence was significantly higher in all primitive HSPC subsets from PKCδ *cKO* as compared to control subsets (Fig [6](#embj2018100409-fig-0006){ref-type="fig"}G). Ultrastructural analysis revealed a significant increase in number, but not size, of mitochondria in HSPCs purified from *cKO* as compared to control BM (Fig [6](#embj2018100409-fig-0006){ref-type="fig"}H). Consistent with this, mtDNA copy number was also markedly increased in PKCδ cKO HSPCs (not shown). Collectively, these results indicate that loss of *PKCδ* increases both mitochondrial number and mitochondrial activity, leading to metabolic priming and increased HSPC energy metabolism. As expected, this increased metabolic activity was accompanied by a moderate increase in reactive oxygen species (ROS) levels, a by‐product of mitochondrial activity, in PKCδ‐deleted *cKO* ST‐HSCs and MPPs, but not in the LT‐HSCs (Fig [6](#embj2018100409-fig-0006){ref-type="fig"}I). Although ROS can be an important endpoint signal for metabolic regulatory pathways implicated in HSC maintenance and function, the functional consequences of ROS‐mediated actions are highly dose dependent. High ROS levels that exceed cellular antioxidant capacity can be detrimental to cell survival, while moderate increases in ROS may potentiate cell survival and proliferation (Ito *et al*, [2006](#embj2018100409-bib-0013){ref-type="ref"}; Ito & Suda, [2014](#embj2018100409-bib-0015){ref-type="ref"}). To test the relationship of increased ROS levels to the *in vivo* expansion of PKCδ‐deleted HSPCs, we treated *cKO* or control mice with *N*‐Acetyl‐L‐Cysteine (NAC), a potent ROS scavenger. NAC treatment was initiated after the last dose of poly (I:C) and continued for 8 weeks (Khandanpour *et al*, [2010](#embj2018100409-bib-0017){ref-type="ref"}). NAC treatment reversed the increased ROS levels in PKCδ‐deficient HSPC to normal levels (Fig [EV5](#embj2018100409-fig-0005ev){ref-type="fig"}B), but had no effect on HSPC expansion (Fig [EV5](#embj2018100409-fig-0005ev){ref-type="fig"}C), suggesting that reducing ROS levels alone is insufficient to rescue the augmented HSPC numbers in PKCδ‐deficient mice. Collectively, these results identify PKCδ as a critical suppressor of HSPC oxidative metabolism and indicate that *PKCδ* deficiency can increase mitochondrial SRC, basal ATP, and ROS levels, thereby supporting the metabolic adaptation of HSPCs during physiological stress.

PKCδ deficiency impacts multiple targets in signaling networks governing HSPC homeostasis {#embj2018100409-sec-0009}
-----------------------------------------------------------------------------------------

To gain further insights into the possible molecular mechanisms through which *PKCδ* restricts HSPC number and function in the steady state, we searched for downstream target genes that were dysregulated in the absence of *PKCδ*. Because PKCδ deficiency significantly altered HSPC cell cycle activity, survival, and metabolism, we focused on genes and pathways previously implicated in the regulation of these properties in HSPCs. Among these, *Bmi1*, a member of polycomb group (PcG) with transcriptional repressor activity, was significantly upregulated in PKCδ *cKO* HSPCs (Fig [7](#embj2018100409-fig-0007){ref-type="fig"}A). *Bmi1*‐deficient adult mice display reduced HSC numbers, profound self‐renewal defects, and impaired competitive repopulation capacity (Iwama *et al*, [2004](#embj2018100409-bib-0016){ref-type="ref"}). Conversely, *Bmi1* overexpression enhances HSPC number and self‐renewal by favoring a shift toward more symmetric (versus asymmetric) stem cell divisions (Iwama *et al*, [2004](#embj2018100409-bib-0016){ref-type="ref"}). Our analyses of PKCδ‐deficient *cKO* HSPCs at 12--16 weeks post‐pIpC identified many phenotypic similarities with *Bmi1*‐overexpressing HSPCs, including increased HSC frequency in adult but not in fetal stages, enhanced competitive repopulation capacity, and augmented self‐renewal. Analysis of additional HSC transcriptional regulators whose loss of function has been associated with enhanced HSC self‐renewal revealed that *Egr1* (Min *et al*, [2008](#embj2018100409-bib-0027){ref-type="ref"}; Gazit *et al*, [2013](#embj2018100409-bib-0008){ref-type="ref"}), *Klf4* (Heidel *et al*, [2013](#embj2018100409-bib-0011){ref-type="ref"}), and *Gfi1b* (Khandanpour *et al*, [2010](#embj2018100409-bib-0017){ref-type="ref"}) are all significantly down regulated in PKCδ *cKO* HSCs (Fig [7](#embj2018100409-fig-0007){ref-type="fig"}A).

![PKCδ deficiency impacts multiple signaling cascade and transcriptional network governing HSPC homeostasis and function\
A--CQuantitative RT--PCR analysis of selected (A) HSPC transcriptional regulators, (B) cell cycle and apoptosis regulators, and (C) known HSPC metabolic regulators expression in bone marrow HSPCs (*n = *4 mice per genotype).D--MIntracellular flow cytometry analysis of Cyclin D1 protein (D); pro‐survival regulators Mcl1, Blc2, and Bim protein (E); representative FACS histograms and bar graphs show relative levels of pAKT (Ser473) relative to WT controls (F); pFoxO3a (Ser253) (G); Total c‐Myc protein (H); pRb (Ser807/811) (I); representative FACS histograms and bar graphs show total PPARγ protein levels relative to WT controls (J); Relative expression levels of total PPARδ protein in HSPCs (K); Activation of pmTOR (Ser2448) (L); pS6 (Ser235/236) and (Ser240/244) (M). Data shown in bar graphs in (D‐M) are mean fluorescence intensity of indicated protein expression in *PKCδ cKO* HSPCs subsets relative to WT controls (*n = *4--6 mice per genotype per target).Data information: The statistical significance of difference was assessed using two‐tailed Student\'s unpaired *t*‐test analysis for comparison of control and *PKCδ cKO* HSPCs. All data are presented as mean ± SEM, \**P* \< 0.05, \*\**P* \< 0.001.](EMBJ-37-e100409-g013){#embj2018100409-fig-0007}

We also examined the expression of lineage priming and differentiation markers in PKCδ‐deficient and control HSPCs. Among the investigated genes, erythroid--megakaryocyte lineage regulators, *Gata1* and *Gata2* were significantly elevated in *cKO* HSPCs, whereas myeloid lineage regulators *Cebp1α* and *PU.1* (*Spi1*) showed equivalent levels of expression (Fig [7](#embj2018100409-fig-0007){ref-type="fig"}A). Despite unperturbed or even elevated differentiation potential, expression of *Id2,* a myeloid and B‐cell differentiation factor and downstream target of β‐catenin activation (Perry *et al*, [2011](#embj2018100409-bib-0032){ref-type="ref"}), was moderately upregulated in PKCδ *cKO* HSPCs, indicating possible activation of β‐catenin in the absence of *PKCδ*. Analysis of cell cycle regulators revealed that expression of *p57* (*Cdkn1c*), previously implicated in HSC cell cycle regulation (Tesio & Trumpp, [2011](#embj2018100409-bib-0040){ref-type="ref"}), is significantly reduced in *PKCδ--*deleted *cKO* HSPCs as compared to control cells, whereas expression of *p18*,*p27* was unaltered (Fig [7](#embj2018100409-fig-0007){ref-type="fig"}B). Despite the significant increase in *Bmi1* transcript levels, its downstream target, *p16* ^*INK4A*^, was unaffected in HSPCs (Fig [7](#embj2018100409-fig-0007){ref-type="fig"}B). *PKCδ* deficiency also caused a significant increase in Cyclin D1 protein (Fig [7](#embj2018100409-fig-0007){ref-type="fig"}D), although the transcript level remained unchanged (Fig [7](#embj2018100409-fig-0007){ref-type="fig"}B). Among the cell survival regulators we explored, protein levels of the pro‐survival mediators Mcl1, Bcl2, and Bim were moderately increased in PKCδ *cKO* HSPCs (Fig [7](#embj2018100409-fig-0007){ref-type="fig"}E), whereas protein levels of pPTEN (Ser380), pBad (Ser136), and PUMA were unperturbed (not shown).

Since loss of PKCδ significantly impacted the metabolic activity of *cKO* HSPCs, we also examined the critical regulators of these metabolic changes. Consistent with the increased OXPHOS and ATP content, expression of mitochondrial respiratory chain components, *ATP5A* (also called complex V), *Cox5a*, and *Cyc1*; expression of oxidative stress responsive gene *Nfe2l2* (*Nrf2*); and expression of *Ldha*, which catalyzes conversion of lactate to pyruvate to generate ATP in the mitochondrial electron transport chain, were all significantly elevated in PKCδ‐deleted *cKO* HSCs (Fig [7](#embj2018100409-fig-0007){ref-type="fig"}C). No change in the expression of *Pdk2* and *Pdk4*, critical regulators of OXPHOS was noted. Nonetheless, this expression pattern fits well with the observed metabolic phenotypes and thus provides a molecular basis for increased metabolic activity of PKCδ‐deficient HSCs.

PKCδ mediates cell context‐dependent signal transduction pathways by phosphorylation of multiple downstream targets. We therefore assessed the effects of PKCδ deficiency on signal transduction in HSPCs. Because *PKCδ* acts upstream of PI3K/AKT, which transduces signals for HSPC survival, proliferation and differentiation through downstream effectors such as GSK3β, mTOR, NF‐Kβ, MAPKs, and FoxO proteins (Tothova *et al*, [2007](#embj2018100409-bib-0041){ref-type="ref"}; Bezy *et al*, [2011](#embj2018100409-bib-0002){ref-type="ref"}; Buitenhuis, [2011](#embj2018100409-bib-0003){ref-type="ref"}; Perry *et al*, [2011](#embj2018100409-bib-0032){ref-type="ref"}; Lechman *et al*, [2012](#embj2018100409-bib-0022){ref-type="ref"}), we measured the individual components of these signaling cascades by intracellular flow cytometry. Total BM cells were starved in serum‐free, cytokine‐free media and stimulated with TPO and SCF. Activation of AKT, measured by elevated phosphorylation at Ser473, and its downstream target FoxO3a, measured by phosphorylation at Ser253, was modestly increased in PKCδ‐deleted *cKO* HSPCs as compared to controls (Fig [7](#embj2018100409-fig-0007){ref-type="fig"}F and G). Expression of c‐Myc, a critical regulator of cell proliferation, mitochondrial biogenesis and metabolism, and phosphorylation of pRb (Ser807/811), a downstream regulator of Cyclin D1 implicated in the G1/S cell cycle transition and mitochondrial biogenesis were also significantly elevated in PKCδ‐deficient *cKO* HSPCs (Fig [7](#embj2018100409-fig-0007){ref-type="fig"}H and I). We found no clear differences in the activation of MAPK signaling components, including p38 and Erk, or in activation of NF‐κB signaling (as measured by phosphorylation of p65 at Ser536) in *PKCδ*‐deleted HSPCs (not shown). Interestingly, PKCδ deficiency had an opposite effect on the expression of peroxisome proliferator‐activated receptor isoforms (PPARs), whose function is implicated in HSPC maintenance (Ito *et al*, [2012](#embj2018100409-bib-0014){ref-type="ref"}). While PKCδ deficiency increased the expression of PPARγ, expression of PPARδ was significantly decreased (Fig [7](#embj2018100409-fig-0007){ref-type="fig"}J and K). Consistent with increased AKT activity, activation of mTOR (Ser2448) and its downstream target pS6 (Ser235/236) were also moderately increased (Fig [7](#embj2018100409-fig-0007){ref-type="fig"}L and M). Collectively, our findings suggest that augmented HSPC expansion and metabolic activity in PKCδ‐deficient mice is a downstream consequence of dysregulation of multiple signaling pathways.

Discussion {#embj2018100409-sec-0010}
==========

The expression and function of PKC isoforms are tissue and context‐dependent (Basu & Pal, [2010](#embj2018100409-bib-0001){ref-type="ref"}; Bezy *et al*, [2011](#embj2018100409-bib-0002){ref-type="ref"}). While a recent study demonstrated that PKCζ/λ isoforms are dispensable for steady‐state and regenerative hematopoiesis (Sengupta *et al*, [2011](#embj2018100409-bib-0039){ref-type="ref"}), our evaluation of PKCδ in HSPC homeostasis and hematopoietic regeneration reveals a critical role for this molecule in HSC proliferation, survival, and metabolic resiliency in both steady‐state and stress hematopoiesis. Interestingly, despite the relatively broad pattern of *PKCδ* expression within the BM compartment, PKCδ‐deficiency results in a rather specific impact on multi‐potent HSPCs, leading to immunophenotypic expansion of LT‐HSC, ST‐HSC, and MPP populations. These data suggest that PKC isoforms play non‐redundant and cell type‐specific functions in regulating HSPC number and functional properties.

Chronic deficiency of PKCδ led to accelerated cell cycle activity and expansion of primitive HSPCs in adult mouse BM, but had little impact on downstream lineage‐committed progenitors or mature cells. The availability and activity of different sets of PKCδ targets in stem and progenitor cells may contribute to the context‐dependent phenotypes. Nonetheless, the observed HSPC expansion phenotype is clearly intrinsic to PKCδ function in the hematopoietic system, as demonstrated by the combined results from inducible deletion and competitive transplantation studies. Although both constitutive and acute deletion of PKCδ in hematopoietic cells results in expansion of the primitive HSPC pool and a slight reduction in myeloid and lymphoid progenitor cell numbers, the reduction in myeloid progenitor numbers was reversed after chronic depletion of PKCδ in *cKO* mice. HSPC expansion in the BM was not accompanied by their increased abundance in peripheral blood as observed in other mouse models of HSPC hyperproliferation, including those lacking *Egr1* or *Gfi1b* (Min *et al*, [2008](#embj2018100409-bib-0027){ref-type="ref"}; Khandanpour *et al*, [2010](#embj2018100409-bib-0017){ref-type="ref"}).

Exploring the potential mechanism(s) of HSPC expansion in *PKCδ‐*deficient mice, we uncovered an enhanced metabolic activity, characterized by increased OXPHOS together with maintenance of glycolytic rate. *PKCδ*‐deficient HSPCs also displayed elevated ROS levels; however, *in vivo* pharmacological treatment with NAC did not impede HSPC expansion in *PKCδ*‐deficient marrow, suggesting that harmonizing ROS levels to the normal physiological range alone is not sufficient to prevent *PKCδ*‐deficiency induced HSPC expansion. Remarkably, at the molecular level, rather than affecting a single regulator or pathway, PKCδ deficiency in HSPCs impacts multiple functionally important targets in interconnected pathways with many feedback and feed‐forward inputs and outputs associated with cell cycle, survival, and metabolism. Extensive mRNA and protein‐level expression profiling to quantify the total and activated signaling components implicated in HSPC biology identified AKT signaling and its downstream components as direct or indirect targets of PKCδ in HSPCs. Although PKCδ deficiency impacts each of these targets only moderately, it appears that this broad deregulation of HSPC signaling has significant functional consequences. We believe that the observed phenotypes are probably due to the cumulative effects of many of these dysregulated pathways. To our knowledge, our study provides the first demonstration that PKCδ acts as an upstream regulator of a network of HSPC regulatory genes, whose concerted deregulation in response to PKCδ loss suggests a previously unexplored connectivity among these disparate factors.

During hematopoietic homeostasis, a large proportion of HSCs reside in a metabolically and proliferatively quiescent state, and their unscheduled activation is detrimental to their long‐term function (Ito *et al*, [2012](#embj2018100409-bib-0014){ref-type="ref"}; Yu *et al*, [2013](#embj2018100409-bib-0046){ref-type="ref"}; Burgess *et al*, [2014](#embj2018100409-bib-0004){ref-type="ref"}; Kohli & Passegue, [2014](#embj2018100409-bib-0019){ref-type="ref"}; Wang *et al*, [2014](#embj2018100409-bib-0043){ref-type="ref"}). These data support the general consensus in the field that active cell cycle state and metabolism are associated with HSC exhaustion leading to BM failure. Consistent with this, we found that *PKCδ*‐deficient HSPCs exhibit accelerated failure in serial challenge with the myelosuppressive agent 5‐FU. On the other hand, our findings in steady‐state and transplant models indicate that deletion of *PKCδ* can augment HSPC pool size by promoting active proliferation while maintaining serial transplantation capacity. These data imply that, at least in certain conditions, HSC functional capacity and self‐renewal is not compromised despite their active state. Similar observations have recently been reported with mice deficient in *Egr1* (in which increased proliferation is accompanied by increased mobilization) (Min *et al*, [2008](#embj2018100409-bib-0027){ref-type="ref"}), *p18INK4a* (Yuan *et al*, [2004](#embj2018100409-bib-0047){ref-type="ref"}), *cAbl* (Rathinam *et al*, [2008](#embj2018100409-bib-0036){ref-type="ref"}), *Itch1* (Rathinam *et al*, [2011](#embj2018100409-bib-0037){ref-type="ref"})*, Gfi1b* (Khandanpour *et al*, [2010](#embj2018100409-bib-0017){ref-type="ref"}), *Llgl1* (Heidel *et al*, [2013](#embj2018100409-bib-0011){ref-type="ref"}), *Dnmt3a* (Challen *et al*, [2014](#embj2018100409-bib-0005){ref-type="ref"}), miR‐126 (Lechman *et al*, [2012](#embj2018100409-bib-0022){ref-type="ref"}), and in *Bmi1*‐overexpressing mice (Iwama *et al*, [2004](#embj2018100409-bib-0016){ref-type="ref"}) in which increased cell proliferation correlated with increased numbers of HSCs and self‐renewal capacity. It remains to be determined whether an active metabolic state contributes to augmented HSPC numbers in these mice as well. Similarly, hyperactivation of PI3K/AKT signaling in mouse models by inactivation of downstream negative regulators such as *Pten*,*Pml*,*GSK3β* (Yilmaz *et al*, [2006](#embj2018100409-bib-0045){ref-type="ref"}; Perry *et al*, [2011](#embj2018100409-bib-0032){ref-type="ref"}; Ito *et al*, [2012](#embj2018100409-bib-0014){ref-type="ref"})*,* and *FoxO* (Tothova *et al*, [2007](#embj2018100409-bib-0041){ref-type="ref"}) results in a transient increase in activated HSCs and has been reported to be accompanied by exhaustion, impaired repopulation capacity, or leukemia (Yilmaz *et al*, [2006](#embj2018100409-bib-0045){ref-type="ref"}). In contrast, *PKCδ‐*deficient mice showed no signs of malignancy over a year follow‐up.

A possible explanation for these unanticipated results is that although a significantly higher percentage of HSPCs exits G0, the absolute number of G0 HSPCs is increased by approximately 2--3‐fold in PKCδ‐deficient mice, due to the increased HSPC pool size in these animals and consistent with the observed increase in hematopoietic repopulating capacity in limit dilution studies. This observation is in line with the paradigm that long‐term blood‐forming potential resides predominantly in the G0 subset of HSPCs. Another possibility to reconcile these findings is that only a fraction of *PKCδ*‐deficient HSPCs are metabolically active and cycling, perhaps related to their particular localization in the BM niche. It is also possible that HSC accumulation in *PKCδ*‐deficient BM results from altered cell cycle division patterns, which may drive a fraction of HSCs to take more symmetric self‐renewal than commitment divisions. In this context, it remains to be determined whether the loss of *PKCδ* induces a shift from glucose to lipid metabolism in HSPCs.

*PKCδ*‐deletion leads to B‐cell hyperproliferation and autoimmunity in mice (Mecklenbrauker *et al*, [2002](#embj2018100409-bib-0026){ref-type="ref"}; Miyamoto *et al*, [2002](#embj2018100409-bib-0028){ref-type="ref"}). Recently, human patients were identified with a homozygous loss‐of‐function mutation (c1840C\>T, p.R614W) in PRKCD (*PKCδ),* resulting in deficient PKCδ expression (Kuehn *et al*, [2013](#embj2018100409-bib-0020){ref-type="ref"}). These patients presented with autoimmune lymphoproliferative syndrome (ALPS) characterized by lymphadenopathy, splenomegaly, and positive autoantibodies due to B‐cell hyperproliferation, a phenotype mirroring the PKCδ knockout mice (Kuehn *et al*, [2013](#embj2018100409-bib-0020){ref-type="ref"}). Although we are not aware of any information suggesting a change in HSPC frequency or function in these patients, our data warrant investigation of such a possibility.

Follow‐up studies will be needed to clarify the respective contributions of specific signaling outputs associated with the observed HSPC phenotypes in *PKCδ*‐deficient mice to determine whether additional PKCδ targets may contribute to increased HSPC pool size and to assess whether loss of PKCδ also augments heterogeneity in myeloid lineage‐committed progenitors (Paul *et al*, [2016](#embj2018100409-bib-0031){ref-type="ref"}). Furthermore, future studies should examine whether PKCδ exerts a similar influence on human hematopoietic stem and progenitors or on other tissue‐specific adult stem cells. In summary, our findings reveal a previously unknown function of *PKCδ* in HSPC homeostasis and regeneration, and suggest that *PKCδ* may act as a rheostat for HSPC expansion. Reversible targeting of PKCδ, alone or in combination with previously known HSPC regulators, may be an attractive strategy for prolonging the maintenance of HSPCs *ex vivo*, and harnessing robust HSPC engraftment function in transplantation therapies.

Materials and Methods {#embj2018100409-sec-0011}
=====================

Mice and treatment {#embj2018100409-sec-0012}
------------------

Constitutive PKCδ knockout mice (Leitges *et al*, [2002](#embj2018100409-bib-0023){ref-type="ref"}) were back‐crossed onto a C57BL/6J background for 14 generations (Bezy *et al*, [2011](#embj2018100409-bib-0002){ref-type="ref"}). To obtain homozygous *PKCδ* knockouts, we intercrossed *PKCδ* ^+/−^ mice. *PKCδ* ^fl/fl^ mice were described in Bezy *et al* ([2011](#embj2018100409-bib-0002){ref-type="ref"}). Mice with *PKCδ* ^fl/+^ *or PKCδ* ^fl/fl^ alleles were crossed with *Mx1‐Cre* ^+^ mice (Kuhn *et al*, [1995](#embj2018100409-bib-0021){ref-type="ref"}) to generate WT; Mx1‐Cre; *PKCδ* ^fl/fl^/*Mx‐1Cre* ^−^ or *PKCδ* ^fl/fl^/*Mx‐1Cre* ^+^ (*cKO*) mice. Deletion of the *PKCδ* floxed allele was induced by injection of polyinosinic polycytidylic acid (pIpC; P1530, Sigma‐Aldrich) at a dose of 500 μg per injection every other day for a total of five injections (i.p.) into 4‐ to 6‐week‐old mice. *PKCδ* ^fl/fl^ mice lacking the Cre transgene (*PKCδ* ^fl/fl^/*Mx‐1Cre* ^−^) were treated in the same way and used as controls. To exclude possible effects of pIpC or interferons on HSCs, *PKCδ* ^fl/fl^/*Mx‐1Cre* ^−^ or *PKCδ* ^fl/fl^/*Mx‐1Cre* ^+^ mice were analyzed at least 4 weeks after the last pIpC injection (Khandanpour *et al*, [2010](#embj2018100409-bib-0017){ref-type="ref"}). Excision of the *PKCδ* allele was confirmed by Western blotting using total protein isolated from sorted Lin^−^Kit^+^ BM cells. B6.SJLPtprca Pep3b/BoyJ (CD45.1) and *Mx‐1/Cre* (B6‐CD45.2*)* mice were purchased from The Jackson Laboratory and maintained at the Joslin Diabetes Center. All experiments involving mice were performed in accordance with the guidelines set by the Institutional Animal Care and Use Committees (IACUC) of Joslin Diabetes Center and Harvard University.

Antibodies and FACS analysis {#embj2018100409-sec-0013}
----------------------------

Total BM cells were harvested from long bones (two tibias and two femurs) by flushing with 25G needle using staining media (Dulbecco\'s PBS+ 5% FCS). Cells were filtered through 70 μm nylon mesh to obtain a single‐cell suspension. Red blood cells were depleted by treatment with erythrocyte lysis buffer (ACK buffer, Lonza). To prevent non‐specific binding of antibodies, cells were incubated with FcBlock (BD biosciences) or Rat‐IgG (Sigma) for 20 min, before staining with fluorescent conjugated antibodies. The following monoclonal antibodies were used for FACS analysis and cell sorting: A mixture of biotinylated monoclonal antibodies CD3, CD4, CD8, CD19, B220, TER‐119, Mac‐1, and Gr‐1 was used as the lineage mix (Lin). Anti‐CD3e (17‐A2), Anti‐CD4 (L3T4), anti‐CD8 (53‐6.72), anti‐B220 (RA3‐6B2), anti‐TER‐119, Gr‐1 (RB6‐8C5), anti‐Mac‐1 (M1/70), APC‐Kit (2B8), CD150 (TC15‐12F12.2, all are from Biolegend); PE‐Cy7‐ or PerCp5.5‐anti‐Sca‐1 (E13‐161.7), APC‐ or FITC‐anti‐CD34 (RAM34), anti‐CD48 (HM48‐1), PE‐Cy7‐CD127 (A7R34) (eBiosciences); PE‐anti‐Flt3 (A2F10.1), PE‐FcγRII/III (2.4G2), FITC‐ant‐CD45.1, PE‐Cy7‐anti‐CD45.2, FITC‐anti‐Ki‐67 and FITC‐Annexin V (BD Biosciences). SYTOX Blue (Invitrogen) was used to exclude dead cells during FACS analysis. Live, singlet cells were selected for gating and cell sorting. Cells were analyzed on a LSRII Flow Cytometer and sorted on a FACSAria‐II cell sorter (BD biosciences). Data were analyzed either using FACS Diva software or FlowJo (version 9.4.4) software (Treestar). The absolute number of particular cell populations was calculated by multiplying the total number of live cells (trypan blue‐negative) by the frequency of the indicated cell population determined by flow cytometry within the live cell (SYTOX Blue--negative) gate or by using cell‐counting beads (BD).

Bone marrow (BM) reconstitution assays {#embj2018100409-sec-0014}
--------------------------------------

For limiting dilution long‐term competitive transplantation assay, graded numbers (7 × 10^3^, 2.210^4^, 6.7 × 10^4^, and 2 × 10^5^) of total BM cells from *PKCδ* ^+/+^ or *PKCδ* ^−/−^ mice were sorted into individual wells of a 96‐well plate containing fixed numbers (2.5 × 10^5^) of CD45.1^+^ whole BM cells and transplanted intravenously into lethally irradiated CD45.1^+^ mice. Sixteen weeks post‐BMT, multi‐lineage donor cell engraftment (CD45.2^+^) was determined by flow cytometry. A recipient mouse was considered positive if donor multi‐lineage engraftment (CD45.2^+^ blood nucleated cells) exceeded 1% in recipient peripheral blood. The frequency of functional repopulating units was calculated according to Poisson statistics using ELDA method (Hu & Smyth, [2009](#embj2018100409-bib-0012){ref-type="ref"}) (ELDA, <http://bioinf.wehi.edu.au/software/elda/>). For competitive transplantation assays, erythrocyte‐depleted total bone marrow cells (BM) (1 × 10^6^) from 8‐ to 12‐week‐old *PKCδ* ^+/+^ or *PKCδ* ^−/−^ mice were mixed with 1 × 10^6^ BM cells (1:1) from recipient type (competitor) and injected intravenously (in 200 μl PBS/mouse) into lethally irradiated (1000rads) CD45.1 (B6.SJLPtprca Pep3b/BoyJ) recipient mice. Hematopoietic reconstitution was assessed in recipient peripheral blood (PB) at the indicated times post‐transplantation. For serial transplantation experiments, primary transplanted mice (described above) were sacrificed after 20 weeks, and 2 × 10^6^ BM cells from each recipient mouse were injected into secondary preconditioned recipients (CD45.1). For HSC (LSKCD48^−^CD150^+^) competitive transplantation experiments, FACS‐purified HSCs (200 cells) from WT or PKCδ KO mice (CD45.2^+^) were mixed with 1 million total bone marrow cells from WT mice (CD45.1^+^) and intravenously transplanted into lethally irradiated congenic WT recipient mice (CD45.1^+^). When using BM cells from conditional *PKCδ* knockout mice, total BM cells (1 × 10^6^) from *PKCδ* ^fl/fl^/*Mx‐1Cre* ^−^ (control) or *PKCδ* ^fl/fl^/*Mx‐1Cre* ^+^ mice were injected along with equal numbers of recipient type BM cells (CD45.1) into the lethally irradiated CD45.1 recipient mice. Recipient mice were allowed to reconstitute for 8 weeks, followed by pIpC injection (five doses) into control and *PKCδ* ^fl/fl^/*Mx‐1Cre* ^+^ mice, as described above. Donor‐derived hematopoietic cells (CD45.2^+^) in PB and BM LSK cells were determined by FACS as described above.

Colony‐forming unit cell assay (CFU‐C) {#embj2018100409-sec-0015}
--------------------------------------

*In vitro* colony‐forming activity was assessed using methylcellulose colony assay with Methocult GF3434 medium (StemCell Technologies). Briefly, freshly isolated BM cells were resuspended in 300 μl of IMDM and mixed in 3.3 ml of Methocult GF3434 medium. Cells were plated in 35 mm culture plate at a density of 1 × 10^4^ BM cells/plate (1.1 ml/plate), in triplicate. On day 12, colonies containing at least 50 cells were scored under an inverted microscope. Differential colony count was performed on the basis of colony morphology, according to the StemCell Technologies criteria.

Cell cycle analysis {#embj2018100409-sec-0016}
-------------------

For Ki‐67 staining, cells were first stained with cells surface antibodies to identify the HSPCs as described above. Cells were then fixed in fixation buffer for 20 min at 4°C, washed twice with permeabilization buffer (BD), and then stained with anti‐Ki67 antibody (BD biosciences) for 30 min at 4°C. Cells were washed once with permeabilization buffer and resuspended in FACS staining buffer containing 20 μg/ml Hoechst 33342 (Invitrogen). For short‐term *in vivo* BrdU incorporation assay, mice were injected (i.p.) with 200 μl of BrdU/PBS solution (10 mg/ml; BrdU kit, BD bioscience). 20 hours after injection, BM cells were harvested and stained with surface makers to identify HSPCs as indicated above. For long‐term incorporation, BrdU was administered orally (1 mg/ml of BrdU in drinking water) for 7 days. Intracellular BrdU staining was performed according to the supplier\'s protocol (BD).

Apoptosis assay {#embj2018100409-sec-0017}
---------------

Erythrocyte‐depleted BM cells (1 × 10^6^) were stained with antibodies to identify HSPC (Lin, c‐Kit, Sca‐1, Flt‐3, and CD34) or myeloid progenitors (Lin, c‐Kit, Sca‐1, F~c~γRII/III, and CD34) as described above. The stained cells were resuspended in 100 μl of Annexin V binding buffer (BD) and incubated with Annexin V‐V450 and 7‐AAD (BD Pharmingen) for 15 min at room temperature. Cells were resuspended in additional 400 μl of Annexin V binding buffer and analyzed immediately using a BD LSR II flow cytometer.

5‐FU treatment {#embj2018100409-sec-0018}
--------------

5‐Fluorouracil (5‐FU) was administered to mice intraperitoneally at a dose of 150 mg/kg. Hematopoietic recovery was monitored by peripheral differential blood counts using Hemavet 950 (Drew Scientific) at indicated time points. For survival assay, 5‐FU was administered intraperitoneally at a dose of 150 mg/kg weekly and survival was monitored daily. When using *PKCδ* ^fl/fl^/*Mx‐1* ^*Cre*−^ or *PKCδ* ^fl/fl^/*Mx‐1* ^*Cre*+^ mice, 5‐FU was injected 30 days after the last pIpC injection.

Metabolic assays {#embj2018100409-sec-0019}
----------------

Real‐time measurement of intact cellular oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) was performed using the Seahorse XF24 extracellular flux analyzer (Seahorse Bioscience) as previously described (Yu *et al*, [2013](#embj2018100409-bib-0046){ref-type="ref"}; Maryanovich *et al*, [2015](#embj2018100409-bib-0025){ref-type="ref"}). Briefly, FACS‐sorted LSK or MyP cells (4--5 replicate wells of 1 × 10^5^ cells per well) were cultured 8 h in StemSpan serum‐free culture medium (StemCell Technologies) supplemented with SCF (50 ng/ml) and TPO (50 ng/ml). Cells were harvested and plated in 24‐well XF24 well plate (Seahorse Bioscience) pre‐coated with BD Cell‐Tak according to the suppliers instructions (BD). One hour prior to measurement, the medium was replaced with unbuffered assay medium, and then, plates were incubated at 37°C in a non‐CO~2~ incubator for 1 h for pH stabilization. For the MitoStress test, respiration was measured both at basal conditions and after sequential loading of ATP synthase inhibitor Oligomycin (350 nm), mitochondrial uncoupler carbonylcyanide 4‐trifluorometh‐oxyphenylhydrazone (FCCP, 10 μM), and electron transport chain inhibitor, rotenone (1 μM) (Seahorse Bioscience). In the glycolysis stress test, respiration was measured both at basal conditions (unbuffered assay medium without glucose) and after sequential loading of glucose (7.5 mM), mitochondrial ATP synthase inhibitor Oligomycin (350 nm), and 2‐deoxyglucose (50 mM; 2DG, a glucose analog, which inhibits glycolysis through competitive binding to glucose hexokinase) (Seahorse Bioscience).

For measurement of glucose uptake, BM cells were incubated at 37°C for the indicated times in StemSpan serum‐free culture medium (StemCell Technologies) supplemented with SCF (50 ng/ml) and TPO (50 ng/ml) with or without 2‐(n‐(7‐nitrobenz‐2‐oxa‐1,3‐diazol‐4‐yl)amino)‐2‐deoxyglucose (2‐NBD glucose, 50 μM, Invitrogen). Cells were then washed once in HBSS and stained with surface markers to define stem and progenitor subsets as described above. Cells were analyzed by LSRII flow cytometer for 2‐NBD glucose fluorescence in the FITC channel.

ATP measurement {#embj2018100409-sec-0020}
---------------

Intracellular ATP levels were determined using the ATP Bioluminescent somatic cell assay Kit (Sigma) following the manufacturer\'s instructions. Briefly, indicated populations were sorted directly into 96‐well assay plate containing PBS (triplicates, 500 cells per well). Cells were incubated with the ATP releasing reagent, and luminescence was immediately quantified using Synergy Mx spectrometer (BioTeK).

Determination of mitochondrial mass {#embj2018100409-sec-0021}
-----------------------------------

For mitochondrial mass determination, total BM cells were incubated with 50 nM of MitoTracker Green (Invitrogen) at 37°C for 30 min after being stained with surface markers. Cells were then washed once with HBSS, and then, fluorescent intensity was measured by flow cytometry for MitoTracker Green in the FITC channel.

Measurement of ROS levels {#embj2018100409-sec-0022}
-------------------------

For measurement of cellular ROS levels, total BM cells were incubated with the redox‐sensitive probe 2′,7′‐dichlorodihydrofluorescein diacetate (CM‐H~2~DCFDA; Invitrogen) (5 μM) at 37°C for 20 min after staining with surface antibodies to define the stem and progenitor subsets as described above. Cells were then washed once with HBSS, resuspended in FACS staining buffer, and analyzed immediately by LSRII flow cytometer for CM‐H~2~DCFDA fluorescence in the FITC channel.

NAC treatment {#embj2018100409-sec-0023}
-------------

The antioxidant N‐acetyl‐L‐cysteine (NAC; Sigma‐Aldrich) was administered orally with the drinking water (10 mg/ml) for 8 weeks. Drinking water with freshly prepared NAC‐supplemented water was replaced every second day. NAC treatment was started 1 week after the last pIpC treatment.

*Ex vivo* HSC expansion {#embj2018100409-sec-0024}
-----------------------

*Ex vivo* expansion of HSCs was performed as previously described elsewhere (Perry *et al*, [2011](#embj2018100409-bib-0032){ref-type="ref"}). Briefly, one hundred LT‐HSCs (LSK CD48^−^CD34^−^CD150^+^) were sorted from WT mice BM and cultured in 96‐well (U‐bottom) in triplicate in StemSpan SFEM medium (StemCell Technologies) supplemented with mSCF (20 ng/ml) and mTPO (20 ng/ml). Cells were treated with or without Mallotoxin (MTX, previously called Rottlerin, 5 μM) or Indolactam V (10 μM) (Abcam) for indicated time. One‐half of the medium was replaced every 3 days. At the indicated days of culture, cells were harvested and analyzed to determine the percent of cells retaining a Lin^−^Sca‐1^+^c‐Kit^+^ phenotype by FACS.

Total and phosphoproteome analysis by intracellular FACS staining {#embj2018100409-sec-0025}
-----------------------------------------------------------------

Erythrocyte‐depleted BM cells were stained with fluorescent conjugated antibodies to identify the HSPC subsets as described above. For measurement of intracellular phosphoproteins and total proteins, cells were starved for 2 h in StemSpan serum‐free medium without cytokines and then stimulated with mSCF and mTPO (20 ng/ml) for 10 min. Cells were then fixed with BD Cytofix buffer for 20 min at 4°C, washed once with 1× Perm/Wash buffer (BD). For measurement of intracellular total protein expression of indicated cell cycle and apoptotic regulators, cells were stained with indicated antibodies without prior starvation and cytokine stimulation. Cells were incubated with Cytopermeabilization buffer Plus for 10 min on ice. After a single wash with 1× Perm/Wash buffer, cells were re‐fixed with BD Cytofix/Cytoperm buffer for 10 min on ice. Cells were washed and incubated with the indicated primary and secondary antibodies for 1 h at room temperature. Cells were analyzed on a LSRII Flow Cytometer. Complete list of antibodies used were listed in [Appendix Table S2](#embj2018100409-sup-0001){ref-type="supplementary-material"}.

Western blotting {#embj2018100409-sec-0026}
----------------

Total protein lysate from the indicated cell types was subjected to standard Western blotting method. Following antibodies were used: rabbit anti‐PKCδ (2058, Cell Signaling Technology) and β‐actin (Santa Cruz).

Electron microscopy {#embj2018100409-sec-0027}
-------------------

FACS‐sorted BM HSPCs (LSKCD135^−^) were pooled from identical genotypes (10^5^ cells per genotype). Cells were fixed overnight in 2.5% glutaraldehyde at 4°C. Cells were pelleted at 3,000 *g* for 10 min at 4°C. Cells were then submitted to Harvard Medical School Electron Microscope Facility for standard transmission electron microscopy ultrastructural analyses. Processed cells were imaged with AMT camera system with direct magnification of 4,800×. Scale bar represents 500 nm. Data are representative of 50 scanned cells per genotype.

Gene expression analysis {#embj2018100409-sec-0028}
------------------------

Total RNA was isolated from the indicated cell types using Trizol or RNeasy Microkit (QIAGEN), and treated with RNase‐free DNase. cDNA was generated with the SuperScript III First‐Strand Synthesis System for RT--PCR (Invitrogen). qRT--PCR transcript levels were determined relative to *β‐actin*. Transcript levels were determined using Taqman probes (FAM) specific for indicated genes. All reactions were performed in duplicate. Complete list of Taqman gene expression probes used are listed in [Appendix Table S1](#embj2018100409-sup-0001){ref-type="supplementary-material"}.

Statistical analysis {#embj2018100409-sec-0029}
--------------------

Statistical analysis was performed with the use of two‐tailed Student\'s unpaired *t*‐test analysis (when the statistical significance of differences between two groups was assessed) or one‐way ANOVAs with subsequent Bonferroni posttest (when the statistical significance of differences between more than two groups was assessed), or two‐way ANOVAs with subsequent Holm--Sidak\'s multiple comparison tests with alpha 0.05 as significant (when comparing between groups; for long‐term reconstitution assays and for hematopoietic recovery analysis) with Prism software version 6.0 (GraphPad Inc). For the Kaplan--Meier analysis of survival curves, a log‐rank nonparametric test (Mantel‐Cox test) was performed. Limiting dilution analysis (LDA) was performed with ELDA (<http://bioinfo.wehi.edu.au/software/elda/>). Significance is denoted with asterisks (\**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001).
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